本帖最后由 老马 于 2012-1-13 21:20 编辑
6 N5 d' ]" Y+ ~% c! P. f
% T+ {! Z& Y- _# L! V爱必妥和阿瓦斯丁的比较9 T2 Q5 t# Y) g9 t" Y, ^# ^
1 K; B( ]7 w; E% fhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ U- s+ ~3 U4 L# r8 y
4 [+ L- V4 T3 ^4 L
% l& O* S) k2 s
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 P- w* l( f0 H4 T/ s4 j
==================================================
/ }3 k% R5 q3 w& j- EOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) n" p% [8 B; H2 z. X- J2 WPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% t/ r4 T: h+ \- ^( }4 z c( V
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.; e4 F7 N) f- D: R( f; b
|
显身卡
2 x+ y( A) D8 {5 ?! Y o a: ~# P
